2025年10月18日,诺和诺德宣布已提交司美格鲁肽口服制剂(Wegovy)的上市申请,预计将在今年晚些时候获得批准。该制剂用于长期体重管理,若如期获批,将为患者提供更便捷的用药选择。此举被视为诺和诺德在肥胖症治疗领域的重要布局,有望进一步扩大其全球市场份额。
Source Link2025年10月18日,诺和诺德宣布已提交司美格鲁肽口服制剂(Wegovy)的上市申请,预计将在今年晚些时候获得批准。该制剂用于长期体重管理,若如期获批,将为患者提供更便捷的用药选择。此举被视为诺和诺德在肥胖症治疗领域的重要布局,有望进一步扩大其全球市场份额。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.